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ABSTRACT
Introduction
Within the past decade, community-associated methicillin-resistant
Staphylococcus aureus (CA-MRSA) infection has become a major health concern. In
human epidermal keratinocytes, S. aureus is mainly recognized through the pattern
recognition receptor toll-like receptor 2 (TLR2) and its co-receptor, cluster of
differentiation 14 (CD14). Cell components or secreted factors from S. aureus likely
augment the virulence of CA-MRSA by directly suppressing keratinocyte innate immune
responses. High mobility group box 1 (HMGB1) is actively released from eukaryotic
cells during infection and can then directly bind to TLR2 to induce inflammation. We
hypothesize that live CA-MRSA bacterial isolates cause recurrent infections in the skin
by interrupting TLR2-mediated inflammation in keratinocytes to a greater extent than
non-recurrent community-associated methicillin-sensitive Staphylococcus aureus (CAMSSA) isolates.
Methods
We asked if recurrent CA-MRSA isolates evade human innate immune responses
in the skin by suppressing TLR2-mediated pro-inflammatory cytokine secretion by
keratinocytes in vitro. We compared the effects of secreted factor exposure and live
infection with recurrent CA-MRSA isolates to the effects of non-recurrent CA-MSSA on
different components of the TLR2 signaling pathway in keratinocytes. A human
x

immortalized keratinocyte cell line (HaCats) was stimulated with bacterial culture
supernatants or live bacterial isolates for 6 hours. Post infection cell culture supernatants
were subjected to ELISA to assess the secretion of pro-inflammatory and antiinflammatory cytokines. Total protein was also extracted from cell lysates post infection
and subjected to Western Blot to assess relative protein levels of TLR2 and CD14, as
well as for the activation and phosphorylation of NFκB.
Results
Exposure to bacterial culture supernatants from recurrent CA-MRSA isolates
resulted in a significant decrease in pro-inflammatory and anti-inflammatory cytokine
and HMGB1 secretion from keratinocytes. Interestingly, live infection of keratinocytes
with recurrent CA-MRSA isolates only revealed a significant decrease in the secretion of
the pro-inflammatory cytokine IL8 by keratinocytes post infection. There were no
significant changes in pro-inflammatory TNFα, anti-inflammatory IL10, or HMGB1
secretion from cells post infection. Additionally, no significant changes in overall
cytokine secretion were observed from keratinocytes treated with live recurrent CAMRSA isolates obtained during subsequent infections of the same patient. Recurrent CAMRSA live infection also did not result in any significant changes in surface receptor
(TLR2 or CD14) expression 6 hours post infection or NFκB activation 15 minutes post
infection in our system.
Conclusions
We conclude that, under our experimental conditions, recurrent CA-MRSA
bacterial isolates do not suppress TLR2-mediated pro-inflammatory cytokine secretion by

xi

keratinocytes by means of cell surface virulence factors. Based on our findings, it is more
likely that recurrent CA-MRSA isolates may utilize a secreted virulence factor(s) to cause
recurrent infection. This effect could then perhaps cause a decrease in recognition of the
pathogen by TLR2 and the host immune system. It is important to further our
understanding of the interactions between recurrent bacterial isolates and the human
innate immune response in order to develop improved treatment and management for this
pathology.

xii

CHAPTER ONE
INTRODUCTION
Within the past decade, the incidence of community-associated methicillinresistant Staphylococcus aureus (CA-MRSA) infections in otherwise healthy individuals
has increased and has become a major health concern. The increasing frequency of these
infections demonstrates the importance of gaining a better understanding of the
pathogenesis of CA-MRSA skin infection in order to progress development of novel
treatment regimens.
S. aureus is a rapidly adapting organism that utilizes a number of different
secreted and cell surface virulence factors to evade host defenses (4, 6, 7, 45). S. aureus
is recognized by Toll-like receptor 2 (TLR2), a major cell surface receptor present on a
variety of human cell types, including keratinocytes. TLR2 requires interaction with one
of its co-receptors (TLR1/TLR6/cluster of differentiation 14 (CD14)), ultimately
resulting in an increase in the innate inflammatory response to infection via intracellular
nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) signaling (6).
TLR2 stimulation and production of pro-inflammatory cytokines can additionally lead to
the release of high-mobility-group box 1 (HMGB1) (19). Under normal cellular
conditions, HMGB1 acts as a DNA-binding protein and transcription factor. Under
inflammatory conditions, such as IL6 and TNFα production, this protein can be
translocated from the nucleus to the extracellular space, where it can then bind TLR2
1
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(13). This binding interaction initiates further TLR2-mediated inflammatory responses
(13) including the secretion of pro-inflammatory (IL6, IL8 and TNFα) and antiinflammatory (IL10) cytokines by keratinocytes.
We hypothesize that recurrent CA-MRSA isolates evade human innate immune
responses in the skin by suppressing TLR2-mediated pro-inflammatory cytokine
secretion by keratinocytes. It is possible that patients with recurrent CA-MRSA infections
are colonized with bacterial isolates that possess or upregulate specific virulence factors
to evade host defenses. This would facilitate the increase in pathogenicity and frequency
of recurrence seen with CA-MRSA isolates. We used the secretion of these cytokines
post infection as an indication of the TLR2-mediated inflammatory responses during
keratinocyte infection in vitro. In all experiments, we compared the effects of recurrent
CA-MRSA infection of keratinocytes relative to the effects of non-recurrent CA-MSSA
and non-recurrent CA-MRSA isolates on downstream TLR2 signaling events in
keratinocytes. The goal of this project was to identify possible mechanisms by which
recurrent CA-MRSA isolates can evade keratinocyte innate immune responses, leading to
their increased pathogenicity, relative to non-recurrent CA-MSSA isolates, and their
increased ability to cause recurrent infection.

Overall Hypothesis
Recurrent CA-MRSA isolates evade human innate immune responses in the skin by
suppressing TLR2-mediated pro-inflammatory cytokine secretion by keratinocytes post
infection.
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Specific Aims
Aim 1: Establish whether recurrent CA-MRSA isolates inhibit key interactions between
TLR2 and its co-receptors or downstream intracellular NFκB signaling necessary for proinflammatory cytokine production to a greater degree than non-recurrent CA-MSSA
isolates using an in vitro model of S. aureus infection in a keratinocyte cell line (HaCats).
Rationale: In preliminary experiments, exposure of normal epidermal keratinocytes
(NHEKs) to recurrent CA-MRSA bacterial culture supernatants exhibited less relative
pro-inflammatory (IL6, IL8 and TNFα) and anti-inflammatory (IL10) cytokine secretion
from keratinocytes than cells that were exposed to MSSA bacterial culture supernatants.
Secretion of these cytokines is at least partially mediated by the TLR2 signaling pathway.
Since TLR2 is the main recognition receptor of S. aureus, perturbations in this pathway
could suppress the innate immune response to infection resulting in decreased recognition
of the pathogen and therefore, increased pathogenicity of the bacteria.
Hypothesis I: Recurrent CA-MRSA isolates inhibit the binding between TLR2 and
its co-receptors, and reduce downstream NFκB activation or translocation as a
mechanism to reduce pro-inflammatory cytokine secretion from keratinocytes.
To test this hypothesis, we will:
Aim 1a: Assess the ability of recurrent CA-MRSA clinical isolates to inhibit the
protein-protein interactions between TLR2 and its co-receptors (TLR1/TLR6/CD14),
a binding interaction that is required for TLR2-mediated pro-inflammatory cytokine
secretion post infection.
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Rationale: TLR2 requires recruitment and binding of co-receptors for activation. This
leads to the translocation of NFκB into the nucleus where it binds DNA and effects
gene transcription, including transcription of pro-inflammatory genes.

Aim 1b: Establish whether recurrent CA-MRSA isolates inhibit NFκB translocation
from the cytoplasm to the nucleus or activation via phosphorylation, resulting in a
decrease in downstream TLR2-mediated pro-inflammatory cytokine release.
Rationale: NFκB translocation from the cytoplasm to the nucleus and nuclear
activation via phosphorylation are required for transcription of downstream TLR2mediated cytokines.

Aim 2: Assess whether recurrent CA-MRSA isolates disrupt HMGB1-DNA binding
interactions at pro-inflammatory cytokine gene promoters, inhibit HMGB1 translocation
from the nucleus to the extracellular space, or hinder extracellular HMGB1/TLR2
binding to a greater degree than non-recurrent CA-MSSA, as mechanisms to decrease
TLR2 mediated pro-inflammatory secretion from keratinocytes.
Rationale: HMGB1 is a multifunctional protein that acts as a DNA binding protein that
can be translocated from the nucleus to the extracellular space during infection. In the
extracellular space, it can bind and activate TLR2 to further progress the secretion of proinflammatory cytokines. Thus, recurrent CA-MRSA isolates may have evolved
mechanisms to impair HMGB1 localization or function in keratinocytes as a mechanism
to enhance pathogenicity.
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Hypothesis II: Recurrent CA-MRSA isolates reduce HMGB1 secretion and
HMGB1 binding to TLR2 as a mechanism to reduce pro-inflammatory cytokine
secretion by keratinocytes.
To test this hypothesis we will:
Aim 2a: Evaluate the ability of recurrent CA-MRSA isolates to disrupt the binding of
HMGB1 to the promoter regions of genes that encode pro-inflammatory cytokines
induced by TLR2 activation.
Rationale: HMGB1 is a nuclear DNA binding protein that is able to bind gene
segments encoding pro-inflammatory cytokines, resulting in decreased proinflammatory cytokine gene transcription.

Aim 2b: Establish whether recurrent CA-MRSA isolates alter the translocation of
HMGB1 from the nucleus to the extracellular space during infection.
Rationale: HMGB1 is normally present in the nucleus but can be translocated to the
extracellular space in response to infection. In the extracellular space, HMGB1 can
bind TLR2 on the cellular surface to further progress the inflammatory response and
therefore, increase the production of pro-inflammatory cytokines.

Aim 2c: Assess whether recurrent CA-MRSA isolates inhibit the protein-protein
binding between TLR2 and HMGB1, and to determine if the addition of exogenous
HMGB1 can reverse the suppression of TLR2-mediated pro-inflammatory cytokine
production.
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Rationale: HMGB1 is translocated to the extracellular space post infection where it
binds TLR2 to further progress the inflammatory response and therefore, proinflammatory cytokine production.

Impact: These studies will further our understanding of how CA-MRSA bacteria are able
to interact with the human host innate immune system in the skin in order to cause
recurrent infection in otherwise healthy individuals. For the first time, we investigated the
innate evasion mechanisms not only of recurrent CA-MRSA clinical isolates between
patients, but also within the same patient during subsequent recurrences. This study also
provides a novel look at the role of HMGB1 during skin infection. It is known that
HMGB1 is secreted by activated macrophages and monocytes after injury or infection
and that HMGB1 in the skin can facilitate wound healing (81) and cell migration (82). In
the context of skin infection specifically, the involvement and mechanism of this protein
remains unexplored. Understanding these mechanisms will allow us to create better and
more specific targets for drug therapies, and will potentially alter the way that we
currently treat recurrent CA-MRSA infections. CA-MRSA is a growing epidemic.
Though there have been studies done looking at CA-MRSA, many of them are genomic
(3, 68) or epidemiologic (49, 51, 54) in nature. This study provides the first look at
possible alterations in the TLR2 signaling pathway in keratinocytes as well as in the
localization or function of HMGB1 in the skin to explain the increased virulence of
recurrent CA-MRSA bacteria.

CHAPTER TWO
INTRODUCTION – LITERATURE REVIEW

Staphylococcus aureus as a prominent human pathogen
Infections caused by Staphylococcus aureus are very important healthcare issues
that are increasing in number and severity resulting in increasing morbidity and mortality
of patients (70). In the United States in 2003 alone, 11 million doctor’s office visits and
over 400,000 inpatient admissions were reported to be due to S. aureus skin infections
(52). These numbers are further increasing due to the emergence of antibiotic resistant
strains. Methicillin-resistant Staphylococcus aureus (MRSA) infections are estimated to
kill about 20,000 hospitalized patients in America each year (53). In 2005 there were an
estimated 94,360 invasive diseases and 18,650 deaths due to MRSA in the US alone,
which is more than HIV (4). These statistics are rising due to the emergence of more
pathogenic community associated MRSA (CA-MRSA) isolates. These facts demonstrate
the importance of gaining a better understanding of the pathogenesis of CA-MRSA skin
infection in order to take steps toward developing novel treatment regimens.
Approximately one third of the human population is colonized with S aureus (15),
but in most cases, these pathogens are commensal and do not cause invasive disease. In
other individuals, S. aureus can be responsible for life threatening infections in several
tissues. Host colonization is the first step in the S. aureus infection process and usually
7
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occurs through direct skin-to-skin contact with a colonized individual. Though this
contact has been identified as a risk factor for colonization or infection, it does not
correlate directly with colonization rates (51). The question then of course is, why do so
few patients who are colonized with S. aureus develop infection? There have been a
number of studies done on S. aureus virulence factors in attempt to identify a single
virulence determinant responsible for this phenomenon (71, 72), but it is more likely that
multiple factors are responsible.

S. aureus and Disease
S. aureus isolates are capable of producing a number of secreted and cell surface
virulence factors that allow them to avoid host defenses in order to cause disease.
Production of these virulence factors is temporally regulated by the bacteria and is
dependent on environmental factors such as cell density and energy availability (4).
Expression of the virulence genes in S. aureus occurs during very particular bacterial
growth phases. For example, in early exponential phase, coagulase, protein A,
fibronectin, and clumping factors A and B are expressed. Throughout the entire
exponential phase, hyaluronidase, δ-hemolysin and entertoxin A are produced. Many of
the other key virulence factors of S. aureus are expressed during post exponential phase
(43). In general, cell surface virulence factors are expressed during exponential growth
phase and secreted virulence factors are expressed during stationary phase (79).
Some examples of staphylococcal secreted virulence factors are superantigens,
proteases, and staphylococcal complement inhibitor (SCIN) (6). Superantigens can over-
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stimulate a T cell response and result in staphylococcal toxic shock syndrome. Bacterial
proteases can cleave and inactivate antimicrobial peptides. SCIN binds and stabilizes
convertases on the surface of the bacteria in order to inhibit all three complement
pathways (6). There are also a number of bacterial cell surface virulence factors that have
been identified in S. aureus. These include the presence of adherence proteins that bind
and inhibit Intracellular Adhesion Molecule-1 (ICAM-1) in order to prevent leukocyte
adhesion and diapedesis as part of the inflammatory response (6). There is also a known
redundancy in the innate immune evasion factors of S. aureus (6, 7). This suggests that a
single molecule or structure is not responsible for the increased virulence of CA-MRSA
isolates. This increase in pathogenicity is more likely due to a network of factors,
potentially involving both soluble bacterial derived proteins and cell surface components.
Strain-dependent effects relating to mastitis outcomes have also been specifically
demonstrated, despite the close genetic relatedness between S. aureus strains tested (78).
For example, there are four restriction modification systems in S. aureus that are known
to be responsible for the ability of the bacteria to take up foreign DNA and to acquire
mobile genetic elements. Particular strains with mutations in these systems are able to
more effectively acquire foreign DNA or mobile genetic elements leading to rapid
acquisition of virulence genes and therefore, enhanced virulence (78).

The Emergence of CA-MRSA as a Public Health Concern
Methicillin resistant Staphylococcus aureus (MRSA) first emerged as a public
health concern in the early 1960s, at which time it was mostly encountered in a healthcare
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setting and affected patients with known immune deficiencies (7). MRSA was first
reported just two years after the introduction of methicillin as a treatment for S. aureus
infection (2), indicating a very high rate of antibiotic resistance acquisition of these
bacteria (7). Within the past decade, community-associated MRSA (CA-MRSA)
infection in patients with no previously identified risk factors has become a major and
growing health concern. CA-MRSA first appeared in the early 1990s and has since
become endemic in a number of countries, with the highest prevalence in the United
States (7). CA-MRSA has most clearly been linked to situations and places where there is
a high chance of skin disruption and close physical contact such as sports locker rooms or
at daycare centers. The increasing numbers of infections and hospital visits due to CAMRSA also indicate the use of additional health care resources and additional cost to the
patient (54). In one study, an economic simulation model estimated the annual burden of
CA-MRSA infections alone to be between 1.4 billion to 13.8 billion dollars per year (55).
CA-MRSA strains have been shown to have enhanced virulence compared to
traditional hospital acquired (HA)-MRSA strains which rarely cause disease outside of
the hospital setting (7). These strains are known to be genetically different from one
another in the sizes of their large chromosome cassettes (SCCmec) (4). HA-MRSA
isolates contain larger SCCmec cassettes than CA-MRSA and CA-MSSA isolates
because they are resistant to a larger range of antibiotics (26).
Additionally, differences in the production of secreted virulence factors by CAMRSA and those produced by HA-MRSA and CA-MSSA strains have been
demonstrated (26). These investigators hypothesized that these differences were due to
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the niche that the bacteria occupied within the host. Since HA-MRSA isolates contain
larger SCCmec cassettes, this may require selection by the bacteria to produce only the
secreted factors that are necessary for the survival of the organism in that particular
environment. An example of this niche dependency is the lower production of toxic
shock syndrome toxin 1 (TSST-1) exotoxin by S. aureus strains in the menstrual, vaginal
mucosa relative to the levels of TSST-1 production by the same S. aureus strain isolated
from the skin (26). This is due to the fact that this toxin is required for skin survival and
causes a great amount of tissue destruction that would be detrimental to the vaginal
mucosa, and therefore, bacterial propagation. Differences in the virulence factors secreted
by CA-MRSA and CA-MSSA isolates have also been found. These investigators
demonstrated that CA-MRSA isolates produce increased amounts of the secreted
superantigenic virulence factors TSST-1 and Staphylococcal enterotoxin C (SEC) relative
to their CA-MSSA counterparts in vitro (26). Though the clinical significance of this
finding is currently unclear, it highlights the possibility that expression levels of virulence
factors may play a role in the increased virulence of CA-MRSA isolates.
Unfortunately, the clinical diagnosis of CA-MRSA is not well defined. At Loyola
University Medical Center, CA-MRSA is classified as such if a MRSA infection is
acquired 48 hours or less after hospital admission. If the infection is acquired after this
time frame then the infection is classified as HA-MRSA. This diagnosis definition is
problematic for a number of reasons. These reasons include the timing of bacterial
cultures depending on clinical symptoms or the fact that S. aureus can colonize an
individual up to years prior to symptomatic infection (29). Additionally, this definition
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does not take any patient factors into account, such as chronic illness or recent antibiotic
treatment. This means that by default, any other infection is classified as communityassociated, even if there are other underlying health complications that could have
resulted in the infection. This definition needs to be further defined in order to better
address clinical management of S. aureus infections.

Innate Immunity and S. aureus
S. aureus has evolved to become very effective at circumventing the host immune
system. The interaction of S. aureus with the innate immune system is of particular
interest because it acts as a first line of defense against pathogens in the body. The first
barrier to bacterial infection is the skin. Epidermal keratinocytes make up the majority of
the cells in the epidermis and are responsible for maintaining the physical barrier between
the internal and external environments. In addition, keratinocytes encode genes for a
number of immune modulators including cytokines, chemokines, and antimicrobial
peptides that are upregulated during times of infection or cellular stress (83).
There are a number of important microbial defense mechanisms in humans that
are known to be essential for clearance of S. aureus including antimicrobial peptides
(AMPs). AMPs are small cationic peptides that have broad spectrum antimicrobial
activity and are secreted by a number of cell types, including keratinocytes. AMP
dysregulation has been implicated in a number of inflammatory diseases, such as atopic
dermatitis and psoriasis (18). Human skin keratinocytes secrete only low levels of AMPs
under healthy conditions, but AMPs are robustly induced in keratinocytes after infection.
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AMPs act as both a natural antibiotic and “alarmins” that further amplify the innate
immune and wound healing responses (18). MRSA strains have even been found to have
increased resistance to the active form of the human cathelicidin antimicrobial peptide
(LL-37) relative to the resistance of this AMP by MSSA strains (12). It remains unclear
whether patients with CA-MRSA infection are colonized with these AMP resistant
strains.
Another important molecule in the study of the interaction between S. aureus and
the host innate immune system is IL-17 and its receptor, IL-17R. T helper 17 (Th) 17
cells are recruited to the site of an infection after TLR2 activation and release of proinflammatory cytokines such as IL-1α, IL-1β, IL-6 and IL-23 (14). Th17 cells also
produce IL-17A and IL-17F which then bind the IL-17 receptor on the surface of
keratinocytes, leading to the production of AMPs (14). Interestingly, it has been found
that human keratinocytes and bronchial epithelial cells produce more AMPs and
cytokines in response to IL17 as compared to other cell types, such as fibroblasts (65).
This highlights the potential of IL17 to be used in therapies against skin and lung
pathogens.
S. aureus interacts with the host immune system through binding of cell wall
lipoproteins to host cell surface receptor Toll-like receptor 2 (TLR2). This leads to the
activation and translocation of the transcription factor, NFκB to the nucleus to induce an
inflammatory response. TLR2, which is expressed by epidermal keratinocytes, has been
found to be a very important receptor in S. aureus pathogenesis. It has been shown that
mice deficient in TLR2 or myeloid differentiation primary response protein 88 (MyD88),
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an adaptor protein required for downstream signaling of this receptor, are highly
susceptible to infection by S. aureus (8). Therefore, CA-MRSA isolates may be able to
cause recurrent infection by subverting the TLR2 recognition pathway in keratinocytes,
leading to a decrease in downstream inflammation.

The TLR2 Signaling Pathway and Skin Disease
Toll-like receptors are a family of transmembrane proteins that act to recognize
pathogenic stimuli in order to elicit appropriate inflammatory responses to infection. In
humans, at least 10 different TLRs have been identified and most of them, with the
exceptions of TLR3 and TLR4, signal through the MyD88 pathway which eventually
triggers NFκB-dependent events (1). In human skin, S. aureus is mainly recognized by
keratinocytes via TLR2, which also requires the recruitment and heterodimerization with
co-receptors TLR1, TLR6 or CD14. Heterodimerization allows these receptors to detect a
wider range of pathogenic targets. For example, TLR2 heterodimerizes with TLR6 to
recognize diacylated lipopeptides, such as macrophage-activating lipopeptide 2
(MALP2). TLR2 can also heterodimerize with TLR1 to recognize triacylated
lipopeptides (9). This receptor then signals through the MyD88 signaling pathway,
ultimately resulting in an increase in translocation of NFκB to the nucleus. NFκB
activation results in production of pro-inflammatory cytokines, chemokines,
antimicrobial peptides (AMPs), and adhesion molecules (6) (Figure 1).
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Figure 1: Summary of TLR2-mediated innate inflammatory responses in
keratinocytes. In human skin, S. aureus is mainly recognized through Toll-like receptor
2 (TLR2) which becomes activated and signals by binding to its co-receptor, CD14 and
acting through the MyD88 signaling pathway, ultimately resulting in an increase in
translocation of NFκB to the nucleus. NFκB signaling results in production proinflammatory cytokines, AMPs, chemokines and adhesion molecules (6).
Alterations or deficiencies in different aspects of innate immunity, including
TLR2-mediated mechanisms, are known to be associated with different inflammatory or
infectious skin disease states. For example, patients with atopic dermatitis (AD) have
been shown to exhibit significantly decreased numbers of TLR2+ peripheral blood
mononuclear cells (PBMCs). This suggests that the deficiency of TLR2 in AD patients
leads to disease pathogenesis (35). Additionally, the balance between pro-inflammatory

16
and anti-inflammatory cytokines is crucial to appropriate immune responses. If this
balance is disrupted, it can lead to variable levels of inflammation that could be
detrimental to the host during infection or disease and therefore, lead to increased
symptoms. For example, significantly decreased levels of cutaneous IL10 mRNA
expression have been identified in psoriasis patients (73). Administration of subcutaneous
IL10 was effective in reducing symptoms of psoriasis in a small number of patients (73),
suggesting that at least a subset of psoriasis symptoms are due to the absence of antiinflammatory cytokines. It is possible that recurrent CA-MRSA isolates are able to
suppress the TLR2 signaling pathway, and therefore downstream pro-inflammatory and
anti-inflammatory cytokine production, leading to an increase in inflammation, disease
symptoms, and/or recurrence.

HMGB1, Inflammation, and Disease
TLR2 stimulation and production of pro-inflammatory cytokines can additionally
lead to release of another nuclear protein, high-mobility-group box 1 (HMGB1). HMGB1
is a ubiquitously expressed and highly conserved chromatin binding factor that acts in the
nucleus to bend DNA and promote protein assembly during normal cellular conditions.
The chromatin is altered by different acetylation patterns in order to allow for the binding
of HMGB1; HMGB1 itself remains unaltered (13). Additionally, this protein is secreted
by activated macrophages and monocytes under inflammatory conditions and is also
known to be passively released from necrotic cells (13). Necrotic cells that are deficient
in HMGB1 have a decreased ability to promote inflammation and mice with HMGB1
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deficiency die within a few hours after birth (13). Apoptotic cells retain their HMGB1,
while necrotic cells release it, which may be a safeguard for the body to prevent
unnecessary inflammation (13).
HMGB1 is able to bind either the receptor for advanced glycation endproducts
(RAGE), TLR2 or TLR4 differentially between cell types in order to initiate further
inflammatory pathways in a systemic manner (Figure 2). HMGB1 binding to RAGE is
known to be involved in chemotaxis and cell migration, while interactions with TLR2 or
TLR4 are known to be associated with increased cytokine production in response to
cellular stimuli (41). HMGB1 activity is associated with the severity of inflammatory
disease (1) and has been implicated in a number of severe inflammatory diseases
including systemic lupus erythematosus (34), rheumatoid arthritis (31), and ankylosing
spondylitis (33). Additionally, high levels of HMGB1 are detected in the circulation of
patients with severe sepsis (42). These facts emphasize the importance of understanding
the role of HMGB1 in the scope of the immune response to injury and infection.
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Figure 2: Summary of HMGB1-mediated innate inflammatory responses in
keratinocytes. TLR2 stimulation and production of pro-inflammatory cytokines can
additionally lead to release of the nuclear protein, HMGB1, from late phase necrotic cells
upon infection. HMGB1 is known to be a transcriptional regulator in the nucleus that
affects the transcription of pro-inflammatory genes in part by NFκB signaling. HMGB1
can be translocated to the cytoplasm and then to the extracellular space where it is then
able to bind to TLR2 in order to initiate further inflammatory pathways in a systemic
manner (1).

MRSA Diagnosis and Treatment
S. aureus infections were initially treated with penicillin and then by methicillin
after penicillin resistance of these bacteria was identified. Just two years after methicillin
began being used, MRSA was identified. MRSA is resistant to all β-lactam antibiotics. In
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MSSA bacterial isolates, there are four penicillin-binding proteins (PBPs) that are
inactivated in the presence of β-lactams. This causes cell death and inhibition of cell wall
biosynthesis (3). MRSA strains have an extra PBP, with a low affinity for β-lactams,
which retains its activity even in the presence of β-lactam drugs. This allows for cell wall
biosynthesis to continue (3).
Currently, MRSA (including CA-MRSA) infections are treated with a variety of
other classes of antibiotics but are continuing to acquire resistance to these antibiotics as
well. For example, heteroresistant vancomycin-intermediate S. aureus (hVISA) has
become an increasing complication in the treatment of MRSA. This resistance pattern is
mediated by the expression of a particular gene in some S. aureus strains that modifies
the structure of the peptidoglycan. This modification causes a loss of affinity of
vancomycin for the peptidoglycan precursor (1). Sub-curative doses of antibiotics are
indicative of the antibiotic levels in a patient who does not follow a consistent treatment
regimen. These antibiotic doses are known to cause clonal expansion of resistant bacteria
in vivo. This allows them to out-compete antibiotic sensitive bacteria (50).
Due to the fast acquisition of antibiotic resistance of S. aureus, a number of
different approaches can be studied in order to find new possible treatments for the
disease including immunomodulatory and vaccination strategies. One of the possible
methods that have been suggested is the activation of TLR2 with an agonist to allow for
increased inflammasome activation post infection (14). Another method could be to
create an intranasal vaccine against Th17 cell-inducing S. aureus antigens to promote
Th17 cell activity and Th17 mediated-cytokine production (14). Due to its rising
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prevalence, it has become increasingly important to understand how CA-MRSA interacts
with the host immune system. This understanding is crucial in being able to efficiently
move toward administration of immune based therapies to treat S. aureus, including
recurrent CA-MRSA infections.

CHAPTER THREE
MATERIALS AND METHODS

Bacterial preparation
For all live infections, we used a protocol adapted from Kisich, et al (21).
Bacterial isolates were grown overnight in 3 mL of tryptic soy broth (TSB) at 37ºC with
shaking. The next day, 150 µl the bacterial overnight cultures were reinoculated into 3
mL of new TSB media and grown up to a concentration of 1.0 x 108 (colony forming
units per milliliter) CFU/mL as determined by optical density (O.D) readings measured
on a Spectromax spectrophotometer. Using a plate blank of TSB media and the path
check function on, OD reads were taken until they were in the appropriate range of 0.751.0. The target OD read was 0.75 which corresponds to a bacterial concentration of
slightly over 1.0 x 108 CFU/mL to allow for some loss of bacteria in subsequent wash
steps. If the OD read was greater than 1.0, the bacteria were diluted appropriately with
TSB until the read was in range. These bacteria were then diluted appropriately to an OD
read of 0.75 and the final volume was brought up to 1 mL with additional TSB. These
samples were then spun down at 4000 RPM for 10 minutes, media was decanted, and 1
mL of sterile 1 X phosphate buffered saline (PBS) was added to each sample prior to a
quick vortex. This cycle was repeated once more before finally resuspending the bacterial
pellet is 1 mL of sterile high glucose, serum free, and antibiotic free Dulbecco’s Modified
21
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Eagle Medium (DMEM) containing sodium pyruvate to give a final working stock with a
concentration of approximately 1.0 x 108 CFU/mL. These bacterial stocks were also
serially diluted and plated onto tryptic soy agar (TSA) plates in order to back calculate
the concentration of each isolate used in the experiments.
HaCat cell preparation
Human HaCat keratinocyte cells were grown up in DMEM with 10% fetal bovine
serum (FBS) and 1x penicillin/streptomycin. The media was changed the day after
splitting of the cells as well as every other day until they reached the appropriate level of
confluency depending on the experiment. The night before treatment, the media was
removed and all cells were washed twice with sterile 1X PBS and serum free and
antibiotic free DMEM were then added in the appropriate volumes to the cells for use in
experiments.
HaCat cell live infection
Appropriate volumes of 1.0 x 108 CFU/mL stocks of each bacterial isolate were
be added to the appropriate size cell culture dishes containing HaCat cells and serum free
and antibiotic free DMEM for a final infecting concentration of 1.0 x 106 CFU/ml and
allowed to incubate for an assay dependent period of time at 37ºC and 5% CO2.
Total protein isolation
After the appropriate incubation time, all cell culture supernatants were removed
and the cells were washed twice with sterile 1X PBS. Then an appropriate amount of
radioimmunoprecipitation assay (RIPA) buffer + Triton X-100 + Pierce HALT
protease/phosphotase inhibitor (Ca. No. 78443) were added to each cell culture dish to
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lyse all cells. These plates were then kept at 20ºC prior to cell scraping to remove all cells
from the cell culture plate. Sonication of all cellular contents was carried out for 10
seconds to break up the cell membranes prior to collection of the cellular supernatant.
BCA Protein Assay
Total protein levels were determined in cell lysates by utilizing Pierce’s
Bicinchoninic acid (BCA) protein assay kit (Ca. No. 23227) per the microplate procedure
provided by the manufacturer. 25 µl of each unknown sample and bovine serum albumin
(BSA) standard (working range 20-2000 ug/ml) were added to a clear 96-well microplate.
Then 200 µl of alkaline working reagent containing BCA was added to each well to
chelate the Cu+2 ions produced from the reduction of Cu+1 by protein in the alkaline
media resulting in a purple color that can be read on a plate reader at 562 nm after 30
minute incubation at 37C.
LDH Cytotoxicity Assay
Post infection cell culture supernatants were used to carry out a lactate
dehydrogenase (LDH) cytotoxicity assay per manufacturer’s instructions (Abcam, Ca.
No. ab65393) to assess the relative levels of cell death between treatment groups and a
vehicle control at various time points between 2 and 24 hours post infection.
Cytokine ELISAs
Cell culture supernatants were collected after 6 hours, spun down at 16000g for
10 minutes to remove any residual bacteria, and used to run ELISAs for the proinflammatory cytokines IL6, IL8 and TNFα as well as for the anti-inflammatory cytokine
IL10 using Peprotech ELISA kits per the manufacturer’s instructions.
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HMGB1 ELISA
Cell cultures supernatants were collected from cell culture dishes 6 hours post infection
with recurrent CA-MRSA, CA-MSSA or control groups. These supernatants were then
spun down at 16000g for 10 minutes to remove any residual bacteria and total protein
was isolated and quantified via BCA protein assay (outlined above). Supernatants were
then used to carry out Biotang’s HMGB1 ELISA (Ca. No. HU8317) to look at secreted
HMGB1 from keratinocytes in culture between groups per the manufacturer’s
instructions.
Western Blots
25-40 µg of protein was loaded to a 12% Tris-HCl gel and ran at 90 volts for
about 1.5 hours. The gel was then transferred to a polyvinyl difluoride (PVDF)
membrane via wet transfer using Biorad tris/glycine buffer + methanol for either 1 hour
at room temperature at 100 mV or overnight at 4ºC at 90 mAMPs. The membranes were
then blocked with either PBS + 0.05% Tween-20 (PBST) or TBS + 0.05% Tween-20
(TSBT). Next, the membranes were probed with one of the following primary antibodies
overnight in block buffer at 4ºC: Rabbit anti-human TLR2 (Abcam, ab108998) at 1:1000
overnight in 5% milk in PBST, Mouse anti-human CD14 (Santa Cruz, UCH-M1) at
1:1000 in 5% milk in PBST, Rabbit anti-HMGB1 (Abcam, ab18256) at 1:1000 in 5%
milk in PBST, Rabbit anti-NFκB (Cell Signaling, D14E12) at 1:000 in 5% BSA in TBST,
Rabbit anti-phospho-NFκB (Cell Signaling, 93H1) at 1:1000 in 5% BSA in TBST,
Mouse anti-β-actin (Santa Cruz, C4) at 1:1000 in 5% milk in PBST, Mouse anti-TATA
binding protein (Millipore, 05-1531) at 1:1000 in 5% milk in PBST, Rabbit anti-TLR1
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(Abcam, ab68153) at 1:1000 in 5% milk in PBST, or Mouse anti-phospho-IκB (Cell
Signaling) at 1:1000 in 5% milk in TBST.
Membranes were then washed 4 times with PBST and probed with an anti-rabbit
or anti-mouse secondary antibody (Vector) as appropriate at a 1:5000 dilution in block
buffer. The blot was then stripped and reprobed as necessary up to 3 times for each blot.
Densitometry was done and all bands were normalized to a loading control in order to
evaluate relative levels of target proteins between recurrent CA-MRSA, non-recurrent
CA-MSSA or control treatment groups.
TLR2 immunoprecipitation (IP)
Total protein concentration in each sample was determined by a using a
colormetric Pierce BCA assay as described above. For the IP procedure, we begin with
~500 µg total protein. Pre-clearance of the samples with 1.5 µl of Rabbit IgG and 20 µl of
protein A/G beads was utilized to remove any non-specific binding that may have
occurred due to the use of the protein A/G beads. After 30 minutes on ice, these samples
were be spun down at 12,000g for 5 mins at 4º C and the supernatants were transferred to
a new tube for use in the experiments. The total protein was then assessed again in the
same way and the maximal amount of protein from each sample was incubated with
rabbit anti-human TLR2 antibody (EPNCIR133) at a concentration of 1:100 overnight at
4ºC with rocking. The next day, 20 µl of protein A/G beads was added to each tube and
incubated at 4ºC with rocking again for 1 hour. The samples were then spun down again
at 17,000g for 5 mins at 4ºC prior to supernatant collection. The pellet containing the
bead/antibody complex was washed twice with 1X PBS, resuspended in 3x protein
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sample buffer, boiled for 5-10 minutes, and put on ice shortly. Appropriate samples were
quick spun to pellet the agarose beads and the supernatant was loaded to a 12% Tric-HCl
gel. The gel was transferred to a PVDF membrane via wet transfer at for either 1 hour at
room temperature at 100 mV or overnight at 4ºC at 90 mAMPs. The membranes were
then blocked with Easy Blot blocking buffer (GenTex) for 30 minutes at room
temperature and then probed with Rabbit anti-human TLR2 at 1:1000 overnight in block
buffer at 4ºC and probed with an anti-rabbit secondary antibody (Vector) at a 1:5000
dilution in block buffer. The blot was then be stripped and reprobed for TLR2 coreceptors (TLR1, TLR6 and CD14) subsequently to assess relative binding of TLR2 to its
co-receptors between groups. Densitometry was done normalized to total TLR2 and a
loading control in order to evaluate relative levels of TLR2 interaction with each of its
co-receptors between recurrent CA-MRSA, non recurrent CA-MSSA or control treatment
groups.
Immunocytochemistry (ICC)
HaCat cells were grown up to ~60% confluency in 8 well chamber slides and
infected with different bacterial isolates in the same fashion as mentioned previously at a
concentration of 106 CFU/mL and incubated at 37ºC for 6 hours. Supernatants were then
removed and cells were washed twice with 1x PBS and then washed six times with 500
µl of 1x Dako wash buffer. The wash buffer was then removed and the cells were fixed to
the slide in 500 µl of acetone for 15 minutes at RT with shaking. After removal of
acetone, the cells were washed three more times with PBS for 5 minutes each and then
incubated in 200 µl of 10% FBS for 30 minutes at RT with shaking. The FBS was then
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removed and the primary antibodies were applied to the cells and kept at 4ºC overnight
with shaking. The next day, the slides were washed six times with Dako wash buffer
prior to incubation with a 1:500 dilution of the fluorescent secondary antibody (FITC
conjugated secondary antibody for CD14 or TLR1 and a Cy3 conjugated secondary
antibody for TLR2) for 1 hour at RT. The slides were then washed 3 more times with
Dako wash buffer and then cover slips were mounted with ~40 µl of Prolong Gold (DAPI
nuclear stain) and dried overnight. A species matched normal IgG was used as a negative
control to make sure that there is no non-specific binding of the primary antibody
resulting in background florescence. The slides were then imaged the next day on the
Evos microscope.
Nuclear/cytosolic protein isolation
HaCat cells were incubated for an assay dependent time point with 1.0 x 106
CFU/mL of bacteria diluted in serum free and antibiotic free DMEM. After incubation,
the supernatant was removed and the cells were washed twice with 1x PBS prior to the
addition of 500 mL of 1x PBS + 5 µl of HALT protease/phosphatase inhibitor to each cell
culture dish. Then isolation of nuclear and cytosolic protein extracts was carried out using
the NE-PER Nuclear and Cytoplasmic Extraction Reagents kit (Thermo Scientific Cat No
78835) per the manufacturer’s instructions.
Addition of exogenous HMGB1
HaCat cells were infected in vitro and 10 ug/mL of exogenous HMGB1 was added at
0 hours post infection with recurrent CA-MRSA or CA-MSSA strains and incubated for
6 hours at 37ºC and 5% CO2.
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Chromatin-immunoprecipitation assay (ChIP)
HaCat cells were grown up to 90% confluence in a 100 mm cell culture dish in 8
mL of DMEM media. Cells were trypsinized with 1 ml of trypsin and 9 ml of DMEM
media added for a total volume of 10 mL. 275 µl of a 37% Formaldehyde solution was
added and the samples were incubated for 15 minutes with rocking. 1 ml of 1.25 M
glycine solution was added to stop the reaction prior to centrifugation at 1500 RPM for 5
minutes at 4ºC. The pellet was then washed with 1 ml of ice-cold PBS and transferred to
a small eppendorf tube and spun again at 1500 RPM for 5 minutes at 4ºC. The next day,
500 µl of a cell lysis buffer with protease inhibitor was added to the pelleted cells and
incubated on ice for 15 minutes with frequent vortexing. Samples were then centrifuged
at 800 g at 4ºC for 5 minutes. The supernatant was removed and discarded and the pellet
was resuspended in 500 µl of nuclear lysis buffer plus protease inhibitor. Samples were
then sonicated five times at power output 4 for 10 seconds each pulse to produce DNA
fragments between 200 bp and 1 kb in size with the majority of them around 500 bp. For
each IP sample, 100 µl of chromatin were diluted in 900 µl of dilution buffer and protease
inhibitor and pre-cleared with 60 µl of protein G agarose for 4ºC for 5-6 hours. The
supernatant was collected via centrifugation and 10 µl saved as input for each sample.
Either an IgG control or antibodies specific for pro-inflammatory genes along with 20 µl
of magnetic beads was added to the remainder of the supernatant and incubated overnight
at 4ºC with rotation. Samples were then spun down and put into a magnet that beads will
attach to, the liquid was then removed and the complex was pelleted by brief
centrifugation and washed sequentially with low salt buffer, high salt buffer, LiCl buffer
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and TE buffer. Chromatin was then eluted from the beads with 100 µl of elution buffer
(SDS, water and NaHCO3) and DNA-protein cross-links were reversed with 8 µl of 5M
NaCl followed by 65ºC incubation for 2 hours followed by a 95ºC incubation for 10
minutes prior to brining the samples to RT. The samples were placed on the magnet
again, the supernatant was harvested and the beads were discarded. DNA purification was
then carried out using an Ultraclean kit for DNA purification (Bioexpress #G-3148-250).
DNA isolated was then analyzed by qPCR and all samples were normalized to the
amount of input DNA.
Statistical Analysis
Cytokine Secretion from NHEK cells during our preliminary experiments was
analyzed via one way ANOVA with a Bonferroni multiple comparison post test where a
P value of .0001 or less was considered significant. All recurrent CA-MRSA isolates
were compared to the MSSA group to determine significance in these experiments. Since
the cytokine secretion from HaCat cells exhibited a large degree of variability, we
compared the medians of the CA-MSSA and recurrent CA-MRSA groups and analyzed
these differences using a Mann Whitney U test for significance in order to account for the
non-normal distribution of data produced by the use of clinical isolates. A p value of 0.05
was considered to be statistically significant. When comparing cytokine secretion
between different bacterial isolates from the same patient, we utilized the means of these
values from 2 independent experiments and represented these in bar graph form
indicating the standard error of the mean (SEM). Finally, in analyzing Western Blot data,
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densitometry values between two independent experiments were averaged and presented
in bar graph form indicating the SEM.

CHAPTER FOUR
EXPERIMENTAL RESULTS

Cytokine Secretion from NHEK cells post exposure to bacterial culture supernatants
It is known that S. aureus is most commonly recognized by host TLR2 surface
receptors that signal through the MyD88 signaling pathway, ultimately leading to
progression of an inflammatory response. We asked if recurrent CA-MRSA isolates
secrete a bacterial factor(s) that is able to suppress TLR2-dependent pro-inflammatory
and anti-inflammatory cytokine secretion from keratinocytes. If recurrent CA-MRSA
isolates suppress the TLR2 pathway via a secreted bacterial virulence factor(s), this could
explain the ability of these isolates to result in more severe, and often recurrent,
infections. In order to assess this possibility, we stimulated normal human epidermal
keratinocytes (NHEKs) in vitro for 24 hours with three day bacterial culture supernatants
from recurrent CA-MRSA or non-recurrent MSSA isolates. The downstream cytokine
secretion from keratinocytes post exposure to either recurrent CA-MRSA or MSSA
bacterial culture supernatants were measured by ELISA and compared to one another.
We found that recurrent CA-MRSA bacterial conditioned media exposure
resulted in a significant decrease in secretion of IL6, IL8, IL10, and TNFα from
keratinocytes (Figure 3). Keratinocytes exposed to recurrent CA-MRSA bacterial culture
supernatants exhibited, on average, a fold decrease of 3.9, 6.0, 2.9, and 2.7 in IL6, IL8,
31

32
IL10, and TNFα secretion, respectively, relative to the cytokine secretion of cells exposed
to MSSA bacterial culture supernatants.
Our samples included recurrent CA-MRSA isolates obtained from a variety of
patients seen at the Loyola University Medical Center and an MSSA lab strain (Sa113).
Table 1 lists the clinical information known about the patients that each of our isolates
were obtained from.
Patient
Initials
2-15 RS
2-35 SB
2-37 FS
2-44 TB

Recurrence
Number
3
5
6
2

Date
1/4/2012
3/20/2012
3/30/2012
4/15/2012

2-57 AA
2-45 AM

1
1

12/9/2011
10/2/2011

2-48 DM
2-59 DD
2-64 RW

2
1
2

5/14/2012
10/31/2011
6/16/2012

Age
56 yrs
40 yrs
70 yrs
35 yrs
10
months
17 yrs
33
months
65 yrs
20 yrs

Sex
M
M
M
M

Source
Left foot
Right foot
Sinus
Ear

F
M

Left gluteal
Right leg

F
F
M

Groin
Abdominal Abscess
Pleural Fluid

Table 1: Clinical information about the recurrent CA-MRSA isolates used in
preliminary bacterial culture media experiments. Each of the isolates in the above
table was used in our bacterial culture supernatant exposure experiments outlined below.
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Figure 3: Pro-inflammatory and anti-inflammatory cytokine release by
keratinocytes after treatment with CA-MRSA bacterial culture supernatants as
shown by ELISA. NHEKs in vitro were treated with a 20% solution of bacterial culture
supernatants from different recurrent CA-MRSA isolates from different patients (labeled
with a letter corresponding to each patient) MSSA Sa113, TSB (negative control) or an
untreated group for comparison. Keratinocytes treated with recurrent CA-MRSA
bacterial culture supernatants exhibited decreased levels of secreted pro-inflammatory IL6, IL-8 and TNFα as well as anti-inflammatory IL-10. *P<.0001 vs. MSSA treatment
group after one way ANOVA with a Bonferroni multiple comparison post test.

HMGB1 secretion from NHEK cells post exposure to bacterial culture supernatants
TLR2 is expressed on keratinocytes and is a known receptor for HMGB1.
HMGB1 binding to TLR2 results in subsequent release and production of proinflammatory and anti-inflammatory cytokines. We then asked if recurrent CA-MRSA
isolates secrete a bacterial factor(s) that is able to suppress HMGB1 secretion from
keratinocytes. Therefore, if recurrent CA-MRSA isolates are able to suppress TLR2
signaling through a secreted factor(s), we would expect the inflammatory effects of
HMGB1 to be dampened as well. To answer this question, we again stimulated NHEKs
in vitro for 24 hours with three day bacterial culture supernatants from recurrent CA-
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MRSA or MSSA isolates. HMGB1 secretion from keratinocytes post exposure to either
recurrent CA-MRSA or MSSA bacterial culture supernatants was measured by ELISA
and compared to one another. We determined that recurrent CA-MRSA bacterial culture
supernatant exposure resulted in a significant decrease in HMGB1 secretion from
NHEKs (Figure 4). Keratinocytes exposed to recurrent CA-MRSA bacterial culture
supernatants exhibited, on average, a fold decrease of 2.4 in HMGB1 secretion relative to
the HMGB1 secretion of cells exposed to MSSA bacterial culture supernatants.

Figure 4: HMGB1 secretion measured from NHEKs exposed to MSSA or recurrent
CA-MRSA bacterial culture supernatants for 24 hours measured by ELISA.
Decreased levels of secreted HMGB1 were observed in supernatants from keratinocytes
treated with recurrent CA-MRSA bacterial culture supernatants. HMGB1 levels were
measured by ELISA and normalized to total protein.*P<.0001 vs. MSSA treatment group
after one way ANOVA with Bonferroni’s multiple comparison post test.
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Cytokine secretion from HaCat cells post infection with live bacteria
Since we demonstrated that recurrent CA-MRSA bacterial culture supernatant
exposure to keratinocytes was able to suppress cytokine secretion, we wanted to
determine if cell-cell contact resulted in a similar decrease in downstream TLR2mediated cytokine secretion. We then asked if live, recurrent CA-MRSA bacterial
isolates were also able to suppress downstream TLR2 pro-inflammatory and antiinflammatory cytokine production. In order to answer this question, we infected HaCat
cells with live, recurrent CA-MRSA, non-recurrent CA-MRSA, or non-recurrent CAMSSA bacterial isolates for 6 hours and compared relative levels of downstream cytokine
secretion by ELISA.
Treatment of keratinocytes with recurrent CA-MRSA isolates resulted in a
statistically non-significant decrease in pro-inflammatory TNFα and anti-inflammatory
(IL10) secretion relative to cells treated with either non-recurrent CA-MSSA or nonrecurrent CA-MRSA (Figure 5). Recurrent CA-MRSA isolate infection did result in a
statistically significant decrease in pro-inflammatory IL8 secretion from keratinocytes
post infection. A similar cytokine profile was observed with increased total cytokine
levels at a 10 hour time point (data not shown). The clinical information of the isolates
used in our live infection experiments are shown in Table 2.
Patient
Initials
FS

TK
CM

Recurrence
Number
1
3
6
1
4
1
4

Date
1/24/2011
7/12/2011
3/30/2012
9/23/2011
11/12/2013
1/21/2011
8/13/2012

Age
69 yrs
70 yrs
70 yrs
50 yrs
52 yrs
84 yrs
86 yrs

Sex
M
M
M
M
M
F
F

Source
Right sinus
Sinus
Sinus
Left leg
Left knee
Right foot
Right arm
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AB
SB

GF
PB

1
4
1
3
5
1
3
3

4/8/2011
1/29/2013
3/16/2011
11/23/2011
3/20/2012
11/4/2011
5/31/2012
5/19/2011

40
42
39
39
40
68
69
63

yrs
yrs
yrs
yrs
yrs
yrs
yrs
yrs

F
F
M
M
M
F
F
F

6

5/31/2013

65 yrs

F

Right hip
Right hip
Right big toe
Right big toe
Right foot
Left arm
Catheter drain site
Abdominal Abscess
Abdominal wall
tissue

Table 2: Clinical information for the recurrent CA-MRSA isolates used in our live
infection experiments. Each of the isolates in the above table was used to infect HaCat
cells for 6 hours as outlined below. We selected an isolate from an earlier and a later
recurrence within each of these randomly selected patients for these studies.

We then compared the effects of recurrent CA-MRSA isolates obtained from the
first recurrence and those obtained from later recurrent infections of the same patient to
determine if recurrence correlated with changes in cytokine secretion. Here, any infection
that occurred at least three months after the initial infection was considered a recurrent
infection. If exposure to isolates from subsequent CA-MRSA infections results in a
decrease in pro-inflammatory and/or anti-inflammatory cytokine secretion from
keratinocytes, this could suggest that these isolates are able to more effectively escape
recognition by the TLR2 signaling pathway in the skin. We utilized the same live
infection cell culture system as described above to assess cytokine secretion from
keratinocytes 6 hours post infection by ELISA. Treatment of keratinocytes with CAMRSA isolates from later recurrent infections revealed no statistically significant
decrease in overall cytokine secretion (Figure 6).
We additionally looked at keratinocyte cytokine profiles post infection with CAMRSA isolates from subsequent infections of the same patient. In some patients (Figure
7, [panels A-C), recurrent CA-MRSA isolates from later recurrences resulted in a non-
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significant increase in overall IL10 secretion by keratinocytes post infection. In other
patients (Figure 7, panels D-E), there was an observed non-significant decrease in IL10.
Levels of TNFα and IL8 secretion from keratinocytes post infection were also not
significantly different in subsequent infections of the same patient (Figure 7).
Interestingly, five different non-recurrent CA-MSSA isolates consistently induced a
similar cytokine secretion profile from keratinocytes post infection (Figure 7, panel F).
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Figure 5: Relative pro-inflammatory (IL8 and TNFα) and anti-inflammatory (IL10)
cytokine secretion levels from HaCat cells 6 hours post infection with either nonrecurrent CA-MSSA clinical isolates, recurrent CA-MRSA clinical isolates, a
vehicle control, or a coagulase negative S. aureus isolate (negative control), as
measured by ELISA. There is a trend toward a decrease in cytokine secretion from cells
treated with recurrent CA-MRSA vs. non-recurrent CA-MSSA isolates. Cytokine ELISA
values of each isolates were averaged from three independent experiments; each dot
indicates the average of the cytokine release of HaCat cells treated with a particular
bacterial isolate. These data were analyzed by comparison of their medians due to the
large variability and p values were obtained using a Mann Whitney U test as follows:
IL10 p = 0.4510, TNFα p = 0.2478 and IL8 p = 0.0307. A statistically significant p value
was designated as 0.05. Statistical significance was only noted in IL8 secretion, though a
trend toward increased IL10 and TNFα secretion from cells treated with recurrent CAMRSA isolates was identified. IL6 was also tested, but levels were very similar to the
vehicle control in most samples and were therefore are not shown here.
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Figure 6: Relative pro-inflammatory (IL8 and TNFα) and anti-inflammatory (IL10)
cytokine secretion levels from HaCat cells 6 hours post infection with recurrent CAMRSA clinical isolates as measured by ELISA and grouped by recurrence. When the
above cytokine data is organized based on the recurrence of the recurrent CA-MRSA
isolate used to treat HaCat cells in vitro, overall patterns can be identified to predict
changes in cytokine production that could be contributing to the ability of these isolates
to cause recurrent infections. Cytokine ELISA values of each isolates were averaged
from three independent experiments; each dot indicates the average of the cytokine
release of HaCat cells treated with a particular recurrent CA-MRSA isolate. These data
were then analyzed by comparison of their medians due to the large variability and p
values were obtained using a Mann Whitney U test as follows: IL10 p = 0.4351, TNFα p
= 0.3543 and IL8 p = 0.9433. No significance was noted, though a trend toward increased
cytokine secretion during later recurrences was identified.
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Figure 7: Relative pro-inflammatory (IL8 and TNFα) and anti-inflammatory (IL10)
cytokine secretion levels from HaCat cells 6 hours post infection with subsequent
CA-MRSA isolates from the same patient during recurrent infections (A-E) or with
CA-MSSA isolates (F) as measured by ELISA. Differences in the cytokine profiles of
cells treated with either non-recurrent CA-MSSA or subsequent recurrent CA-MRSA
bacterial isolates from the same patient can be seen. Panels A-E show the cytokine
profiles of cells treated with different recurrent CA-MRSA isolates from subsequent
infections of the same patient. Panel F shows the cytokine profiles of the non-recurrent
CA-MSSA isolates utilized in our studies.
Total protein expression of surface receptors in HaCat cells post infection with live
bacteria
TLR2 is known to require recruitment of and interaction with one of its coreceptors, most commonly CD14, in order to recognize different lipopeptide structures on
the surface of pathogens resulting in an innate immune response. Therefore, the next
question that we asked was whether infection with recurrent CA-MRSA isolates results in
a decrease in total protein levels of host surface receptors TLR2 and CD14 in
keratinocytes. If recurrent CA-MRSA isolates decrease the total protein levels of TLR2
and/or CD14 in HaCat cells post infection, we would expect to see a decrease in proinflammatory (IL8 and TNFα) and anti-inflammatory (IL10) cytokine production in
response to infection. In order to address this experimental question, we performed total
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protein Western Blots on whole cell lysates from HaCat cells infected with non-recurrent
CA-MSSA, non-recurrent CA-MRSA, or recurrent CA-MRSA isolates for 6 hours. These
blots indicated relatively similar total levels of both TLR2 and CD14 in keratinocytes
infected with non-recurrent CA-MSSA, non-recurrent CA-MRSA, and recurrent CAMRSA isolates (Figure 8). The average densitometry values of each of the above groups
in two independent experiments were determined and normalized to the loading control,
β-actin (Figure 8). The medians of the recurrent CA-MRSA treated group were compared
to the medians of the non-recurrent CA-MSSA and non-recurrent CA-MRSA groups,
revealing a non-significant change in total TLR2 and CD14 protein expression at 6 hours
post infection..
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Figure 8: Western blot analysis of total HaCat cell lysates 6 hours post infection
with MSSA isolates or recurrent CA-MRSA isolates with corresponding
densitometry values normalized to B-actin suggesting relatively stable levels of
TLR2 and CD14 post infection. Levels of total TLR2 remained relatively unchanged at
this time point post infection. A dramatic increase in CD14 was also indicated in all
MSSA (black bars) and recurrent CA-MRSA (gray bars) infected groups when compared
to the negative control vehicle and coagulase-negative S. aureus treated groups as
expected under infection conditions, but the levels between the infection groups were
very similar and not statistically significant. These graphs show results from one
experiment that was repeated again with similar results. P values were obtained using a
Mann Whitney U test to compare MSSA and recurrent CA-MRSA treated groups; p
values were as follows: TLR2 p=0.8438, CD14 p=0.7756. TLR1 was also imaged, but
the band was very difficult to capture, but also appeared not to vary significantly between
groups.
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NFκB activation in HaCat cells post infection
Activation of the TLR2 signaling pathway ultimately leads to the phosphorylation
and activation of the transcription factor, NFκB, which then leads to the upregulation of
genes encoding for chemokines, cytokines, cell adhesion molecules, and AMPs (6). We
next wanted to assess the ability of recurrent CA-MRSA isolates to inhibit NFκB
activation via phosphorylation, which is a necessary event leading to downstream TLR2mediated cytokine release. To answer this question, we carried out total phospho-NFκB
Western Blots in order to compare the relative levels of NFκB activation between
keratinocytes treated with recurrent CA-MRSA and non-recurrent CA-MRSA or CAMSSA isolates. Since NFκB activation occurs very rapidly after infection, we assessed
the total relative levels of NFκB and phospho-NFκB 15 minutes post infection with our
bacterial isolates. If recurrent CA-MRSA isolates are able to inhibit the phosphorylation
of NFκB, then we would expect to see a decrease in downstream pro-inflammatory and
anti-inflammatory cytokine production. We found that keratinocytes infected with
recurrent CA-MRSA isolates did not exhibit a significant change in the levels of total
phospho-NFκB at 15 minutes post infection in our system (Figure 9).
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Figure 9: Western blot analysis of total HaCat cell lysates 15 minutes post infection
with MSSA isolates or recurrent CA-MRSA isolates with corresponding
densitometry values normalized to total NFκB. These data (using the mean of the
normalized densitometry values of two experiments) suggest relatively similar levels of
NFκB activation post infection. An overall increase in NFκB activation was observed
when compared to the negative control vehicle and coagulase-negative S. aureus treated
groups as expected under infection conditions, but these levels were relatively stable
among treatment groups and not statistically significant. A p value was obtained using a
Mann Whitney U test to compare CA-MSSA and recurrent CA-MRSA treated groups;
p=0.8639.
HMGB1 secretion from HaCat cells post infection
HMGB1 is a danger associated molecular pattern (DAMP) that translocates from
the nucleus to the extracellular milieu, upon TLR2 stimulation to elicit pro-inflammatory
effects through NFκB activation. The next question that we investigated was if recurrent
CA-MRSA isolates inhibit HMGB1 secretion from keratinocytes post infection as a
mechanism to evade recognition by the host immune response. In order to answer this
question, we carried out HMGB1 ELISAs on cell culture supernatants 6 hours post
infection with recurrent CA-MRSA, non-recurrent CA-MRSA, and non-recurrent CA-
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MSSA isolates. If recurrent CA-MRSA isolates inhibit the translocation of HMGB1 from
the nucleus to the extracellular space, we would expect to see decreased secretion of
HMGB1 from keratinocytes treated with recurrent CA-MRSA isolates. Infection of
keratinocytes with recurrent CA-MRSA isolates did not exhibit a significant decrease in
HMGB1 secretion 6 hours post infection in our system (Figure 10).
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Figure 10: Relative HMGB1 secretion from HaCat cells 6 hours post infection with
either non-recurrent CA-MSSA clinical isolates, recurrent CA-MRSA clinical
isolates, a vehicle control, or a coagulase negative S. aureus isolate (negative
control), as measured by ELISA. Stimulation of HaCat cells for 6 hours with live
bacterial isolates resulted in no significant difference in HMGB1 secretion between CAMSSA and recurrent CA-MRSA treated groups, indicating that recurrent CA-MRSA
bacteria are probably not affecting the secretion of this protein as a mechanism to cause
decreased inflammatory response and immune avoidance during infection. A p value
were obtained using a Mann Whitney U test to compare MSSA and recurrent CA-MRSA
treated groups; p=0.6931.
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HMGB1 localization in HaCat cells post infection
The function of HMGB1 is dependent on its location within the cell. Under
normal conditions HMGB1 acts as a DNA-binding protein and transcription factor in the
nucleus (1). Under inflammatory conditions, such as IL6 and TNFα production, this
protein can be translocated from the nucleus to the cytoplasm. In the cytoplasm it is
packaged into vesicles prior to its secretion into the extracellular space, where it can then
bind TLR2 (1) in order to amplify the inflammatory response. We then asked if recurrent
CA-MRSA isolates inhibit the translocation of HMGB1 from the nucleus to the
cytoplasm, or from the cytoplasm into the extracellular space in keratinocytes post
infection. In order to answer this question, we carried out ICC assays on keratinocytes 6
hours post infection with either recurrent CA-MRSA or non-recurrent CA-MSSA isolates
in order to compare relative levels of HMGB1 localization by utilizing a fluorescently
conjugated HMGB1 antibody. Similarly, if recurrent CA-MRSA isolates inhibit the
translocation of HMGB1 from the cytoplasm to the extracellular space, we would expect
to see increased levels of cytoplasmic HMGB1 in keratinocytes infected with these
isolates. Unfortunately we were not able to address this question using this method due to
technical complications. Here, the fluorescent signal due to the bacteria binding the
fluorescently conjugated secondary antibodies was very high and it was difficult to
determine localization of HMGB1 in the cells treated with the bacteria groups (Figure
11).
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Figure 11: HMGB1 localization via ICC with vehicle treated and CA-MRSA treated
groups. Here, ICC was carried out using an HMGB1 specific antibody or IgG isotype
control at 6 hours post infection. The vehicle treated cells show high levels of HMGB1 in
the nucleus as expected under normal conditions and no staining in the IgG control
indicating no non-specific binding of the antibody. The CA-MRSA treated group exhibits
high levels of punctate staining that is localized to the bacteria on the slide and is also
present a high degree in the IgG control. This FITC signal is so high in the CA-MRSA
infected cells that I am not able to visualize the cells in the vehicle and infected groups
under the same microscope conditions, so valid comparisons can not be made between
groups at this time. Additional troubleshooting will be needed in the future to answer our
experimental questions regarding localization and co-localization in infected cells with
immunoassays due to the presence of protein A as discussed previously.

CHAPTER FIVE
DISCUSSION
Taken together, our data provide some insight into the inflammatory effects of
different clinical recurrent CA-MRSA and non-recurrent MSSA isolates on keratinocytes
in vitro. It is important to identify differences in the immune response against these
pathogens in order to understand why CA-MRSA isolates possess enhanced virulence
and are often able to cause recurrent infections in otherwise healthy individuals. If
particular mechanisms underlying the interactions between the bacteria and the host
immune system are identified, these pathways could serve as targets for improved
treatment of CA-MRSA infections, particularly those that result in recurrence.
In all of our analyses we compared the effects of recurrent CA-MRSA isolates on
keratinocytes to the effects of non-recurrent CA-MSSA isolates under the same
experimental conditions. Non-recurrent CA-MSSA isolates were the appropriate
comparison to recurrent CA-MRSA isolates because of their evolutionary background.
CA-MRSA is thought to have emerged from CA-MSSA, as opposed to HA-MRSA, due
to the sizes of their SCCmec cassettes (24). Therefore, making a comparison between
recurrent CA-MRSA and non-recurrent HA-MRSA would be potentially misleading in
our mechanistic analyses but could be pursued in later phases of this project.
Additionally, in later experiments, we included a few non-recurrent CA-MRSA bacterial
isolates in our analysis and determined that there appears to be similar variability and
48
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patterns in cells treated with these isolates. The sample size for these isolates was very
small with only three isolates and could be pursued on a larger scale in the future.

Exposure of keratinocytes to recurrent CA-MRSA bacterial culture supernatants
TLR2 is known to be the main recognition receptor of S. aureus, therefore, it is
reasonable to speculate that CA-MRSA is able to cause recurrent infections by
circumventing TLR2 recognition and signaling. Differences are known to exist between
the production of secreted virulence factors, such as superantigens, by CA-MRSA and
CA-MSSA (26). In our initial preliminary experiments, we grew up different recurrent,
clinical CA-MRSA isolates and an MSSA (Sa113) isolate in culture for three days prior
to collecting the culture supernatants. These supernatants included any factors that the
bacteria secreted in the three day time frame as well as any shed cell wall components.
We demonstrated that exposure of NHEKs to recurrent CA-MRSA bacterial culture
supernatants resulted in a significant decrease in secretion of pro-inflammatory (IL8, IL6
and TNFα) and anti-inflammatory (IL10) cytokines post infection. Additionally, we saw
an increase in total levels of HMGB1 and a decrease in the secretion of HMGB1. These
findings suggested that a secreted or shed cell wall component(s) produced by recurrent
CA-MRSA isolates was able to decrease the innate immune response in the skin to a
greater degree than the MSSA isolate tested. These effects could have been mediated by a
cell wall component(s) such as lipoteichoic acid, or by a secreted virulence factor(s)
produced by the bacteria at some point during the three day time course.
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One possible explanation for the observed decrease in presumed TLR2-mediated
cytokine secretion from keratinocytes after exposure to recurrent CA-MRSA bacterial
culture supernatants, is the secreted S. aureus virulence factor staphylococcal
superantigen-like protein 3 (SSL3) (36). This family of staphylococcal superantigen-like
proteins is becoming of increasing interest due to their described ability to mediate
immune evasion. SSL3 is able to specifically bind the extracellular domain of TLR2 on
neutrophils and monocytes in mice leading to a reduction of downstream cytokine
production (36). Since keratinocytes are also known to express TLR2, we hypothesize
that this virulence factor is upregulated by recurrent CA-MRSA isolates. This would also
explain why we were unable to reproduce the decrease in TLR2-mediated cytokine
secretion by keratinocytes in our live infection model as the bacteria were washed prior to
infection, removing any secreted factors that they may have produced. Additionally, the
six hour infection that was utilized would possibly not have been enough time to produce
enough of this virulence factor to cause a noticeable effect in downstream TLR2
signaling in our system.
It has also been shown that bacterial culture supernatants of the Staphylococcus
epidermidis, were able to activate TLR2 signaling resulting in an increase in the
production of AMPs and increased defense against infection (74). This study further
highlights the possibility that secreted virulence factors, even of commensal species, are
able to affect host signaling pathways. It also showcases a limitation of our cell culture
model. In our model, we do not have the effects of other bacteria, including commensals,
which could also be playing a role in the establishment of recurrent infection.
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Heterogeneity in the effects of live infection of keratinocytes with recurrent CA-MRSA
isolates in vitro
We speculated that cell-cell contact between recurrent CA-MRSA isolates and
keratinocytes may also be involved in the observed suppression of the inflammatory
response, acting as a possible contributing factor in the pathogenesis of recurrent CAMRSA infection. An in vitro model using the immortalized HaCat cell line was utilized
to allow us to asses the ability of recurrent CA-MRSA isolates to suppress TLR2mediated pro-inflammatory cytokine secretion from keratinocytes during infection. Our
data suggested that there was a large degree of heterogeneity in downstream TLR2
inflammatory events in cells treated with recurrent CA-MRSA and non-recurrent CAMSSA isolates in keratinocytes.
The observed decreases in relative levels of cytokine secretion, surface receptor
expression, or NFκB activation were likely not statistically significant due to the large
biological heterogeneity in the inflammatory response post infection between individual
isolates. We knew very little clinical information about the patients that our isolates were
obtained from. There are a number of host and environmental factors that could have
affected the bacteria isolated. These include the severity of the infection at the time of
bacterial isolation, if the patient was on a current or recent antibiotic regimen, or even the
genetic dispositions or other comorbidities of these patients. All of these factors have the
potential to influence the environment in which the bacteria are adapting and could affect
their overall physiology and pathogenicity. Additionally, the isolates that we investigated
were not strain typed so it was unclear if the same bacterial strain is the one that is
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responsible for recurrent infections or if they are different strains. This is something that
should be investigated in the future to better understand if recurrent infections are due to
the adaptation of the bacteria or if they are due to host factors.
Another recent study utilized human embryonic kidney (HEK) cells transfected
with TLR2 activity in order to assess the ability of different clinical S. aureus isolates to
stimulate TLR2. Here, IL8 cytokine production was used as a readout of TLR2 activation
24 hours post infection (46). This experimental set up was similar to ours and these
investigators also identified a large degree of heterogeneity in the TLR2 activity
exhibited by different S. aureus isolates as we observed in our studies. These
investigators also compared TLR2 activation post infection of HEK cells with isolates
obtained from patients with either cystic fibrosis or invasive disease. They found no
correlation between the origin of the isolate and the TLR2 activity (46). Our findings
extend these observations in that we observed a similar pattern in keratinocytes
stimulated with clinical non-recurrent CA-MSSA or recurrent CA-MRSA isolates for 6
hours. Additionally, these investigators looked at a variety of cellular processes to
discover which one(s) were responsible for these changes in TLR2 activity. They
discovered that this activity appears to be due to a variety of factors including
proliferative activity, capsule formation, protein synthesis and cell wall factors (46).

HMGB1 function during recurrent CA-MRSA infection
It is known that mammalian cells do not produce new pools of HMGB1 until
about 16 hours post stimulation (27). The HMGB1 utilized and secreted by the cell prior
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to this time point is from a preformed nuclear store of this protein (27). Therefore, we
would not expect to see any changes in the total HMGB1 levels, which we observed in
our system via Western Blot (data not shown). We were unfortunately limited with our
cell culture model in terms of the amount of time that we could expose our cells to the
live bacteria in culture prior to killing the cells. Importantly, we were still able to assess
the secretion of HMGB1 into the extracellular space post infection. This allowed us to
determine that recurrent CA-MRSA isolates do not suppress the secretion of HMGB1
from keratinocytes post infection relative to the levels of HMGB1 secretion from nonrecurrent CA-MSSA treated groups. This indicated that there was not a variation in the
amount of HMGB1 in the extracellular space available to interact with TLR2 at the cell
surface that could stimulate the TLR2 signaling pathway. Since recurrent CA-MRSA
isolates did not result in a significant decrease in pro and anti-inflammatory cytokine
secretion from keratinocytes post live infection, we did not carry out the initially
proposed addition of exogenous HMGB1 experiments. Therefore, HMGB1 secretion was
not affected by recurrent CA-MRSA cell surface virulence factors leading to recurrent
infections under our experimental conditions. Although, HMGB1 secretion was
decreased after exposure to secreted factors from recurrent CA-MRSA isolates. Due to
these findings, it is possible that a secreted virulence factor(s), as opposed to a cell
surface virulence factor, may be responsible for the ability of these bacteria to cause
recurrent infections in otherwise healthy individuals.
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Limitations of our in vitro keratinocyte infection model
There were a number of limitations in our live infection cell culture model. We
were limited in the amount of time that we could expose the cells to the live bacteria. We
chose the 6 hour time point after performing an LDH cytotoxicity assay (data not shown).
Cell death was assessed at different time points 2-24 hours post infection and revealed
that after 8 hours, there was increased cell death and cellular morphology changes in
keratinocytes infected with live bacteria. We also based our time point on a study looking
at the kinetics of cytokine production after LPS stimulation of human whole blood (25).
This study determined that TNFα protein production peaked about 4-6 hours post
infection before stabilizing and that IL8 protein increased initially up to about 6 to 12
hours post stimulation (25). Though this was a very different system than ours, it was a
helpful starting point to determine when we would be able to see changes in protein
expression in our cells post infection. It has also been found that peak cytokine responses
post infection of cells with Gram positive bacteria occurs 50 to 75 hours after the
challenge, as opposed to 1 to 5 hours after a Gram negative challenge (57). This means
that we may have needed to expose our cells to the live bacteria for much longer than 6
hours to see changes in the response of the keratinocytes post infection. A possible way
to address this limitation in the future could be by using heat killed bacteria so that their
cell wall components would still be exposed to the cells. Here, the bacteria would not be
dividing and invading cells so the cytokine profiles could be examined for longer periods
of time. The problem with this method is that if the bacteria are not growing and dividing,
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then infection conditions are not being replicated which could lead to a different immune
response by the host cells.
Our system was also limited to looking at the effects of CA-MRSA isolates on
keratinocytes alone and vice versa. It is also likely that there are other confounding
factors that my influence these interactions in vivo and with the contributions of other
immune cells and cellular processes. Additionally, the cytokine secretion profiles that we
investigated would directly and indirectly affect the recruitment and activity of other
immune cell types. For example, IL10 and TNFα have been shown to play bilateral roles
during injury and infection (11). IL10 is an anti-inflammatory cytokine that skews the
immune response toward a Th2 response by promoting B cell survival and proliferation.
TNFα is a pro-inflammatory cytokine that is known to activate macrophages. And finally,
IL8 is another pro-inflammatory cytokine that is produced in response to infection and
plays a role in neutrophil activation and recruitment to sites of infection. Therefore, the
production of these cytokines is only one aspect of the host immune response to infection
that could be affected by recurrent CA-MRSA virulence factors.

The challenge of live bacterial infection in vitro
Working with live bacteria posed a number of problems in regards to our assays
and much troubleshooting was done to try to overcome these obstacles. It is important to
note some of these challenges in order to address them more effectively in future studies
in the field.
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The largest problem was trying to find ways to overcome the antibody binding
activity of the S. aureus virulence factor, Protein A. Since we infected cells with S.
aureus bacteria for 6 hours prior to collection, the cells contained bacteria that were
internalized during the incubation period. Protein A is a virulence factor secreted by S.
aureus that binds the Fc portion of immunoglobulin molecules to prevent opsonization
and antibody recognition of the pathogen (6). This protein was a problem when trying to
carry out the initially proposed co-immunoprecipitation experiments to assess for proteinprotein interactions between TLR2 and its co-receptors. The protein A that was contained
in the bacteria used in the assay was presumably leading to nonspecific binding of the
antibodies utilized. We saw heavy bands appearing around 50 kD and 25 kD (data not
shown) which we presume were showing up where the antibodies were recognizing the
heavy and light chains of the TLR2 antibody used in the pull down. This problem would
have prevented us from visualizing CD14 and HMGB1 via co-immunoprecipitation due
to their molecular weights that are close to that of the heavy chain (~50 kD).
To solve this problem, we tried to utilize protein G beads (as opposed to protein
A/G beads) for the Co-IP experiments but we were still detecting the problematic bands
as encountered previously. The likely reason for this was that after complete cell lysis,
protein A was present in high amounts and able to bind the Fc regions of any IgG
molecules, including the Rabbit IgG used in the pre-clear step, the primary antibodies,
and the secondary antibodies. During the pre-clearance step we did add a large amount of
normal rabbit IgG to remove any non-specific binding and to allow for the removal of
protein A from our samples. It is likely that this did not remove all protein A from the

57
sample. The protein A that remained would then be able to competitively bind with the
primary antibody and lead to decreased efficiency of the pull down of the protein of
interest. This additionally results in the pull down of protein A and therefore, a large
amount of the primary antibody along with it, which are then visualized on the Western
Blot downstream. We used an easy blot secondary antibody (Genetex, Ca. No.
GTX221666-01) that only recognizes non-reduced antibodies and should not detect bands
due to the heavy and light chains. Unfortunately, the protein A can also bind the
secondary antibody non-specifically resulting in visualization of the IgG heavy and light
chain bands by Western blot. This was also likely the reason why using a primary
antibody from a different species also resulted in bands where we would expect the heavy
and light chains, since protein A does not differentiate between species of IgG. This
problem is likely not encountered in straight Western Blot assays, because the amount of
protein A with all of the other proteins present in the sample is minute, while in the Co-IP
protocol, these lysates are concentrated.
With these considerations and experiences in mind, and in the interest of time, we
decided to use an ICC protocol that was well established in the lab to look at the colocalization of TLR2 and its co-receptors. This method does not give a direct indication
of protein-protein interactions but instead provides strong evidence for co-localization
between TLR2 and its co-receptors, which is required prior to TLR2 activation.
Unfortunately, this assay posed its own challenges as well. In the ICC protocol, the cells
that were infected with the bacteria were binding to the fluorescent antibodies and
producing non-specific florescent staining (Figure 11). This non-specific staining was
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slightly improved by changing the blocking reagent to a solution of 10% heat inactivated
FBS, as opposed to the superblock reagent (Scytek Laboratories, Cat. No. AAA125), but
this did not solve the problem. This was likely due to the large amounts of bacteria that
remained on the slides even after additional wash steps. Increasing the FBS concentration
and/or blocking time (>30 minutes) may further solve this problem, but it should be noted
that we are not aware of any higher concentrations of FBS being used in assays such as
these. It might be beneficial to test varying concentrations of FBS on the efficiency of the
block while also being careful not to over saturate the system with antibodies. Also, a
number of our antibodies that we purchased for use in these experiments did not work
well in HaCat cells under out experimental conditions with either acetone or
paraformaldehyde fixation. We could not visualize any staining by some of these
antibodies on our Evos microscope. We did try to use deconvolution microscopy to
determine if the signal produced by these antibodies was just very low due to the
conditions in my system, or if the antibodies were not binding appropriately to the cells.
This method utilizes a number of mathematical algorithms to analyze images from
different focal planes and combines them to form a clearer three dimensional image (67).
After doing this, we were still unable to see any florescent signal except for the signal
that was due to the bacteria binding the secondary antibody (data not shown). The colocalization of CD14 and TLR2 in human monocytes after LTA exposure has been
demonstrated successfully with the use of confocal microscopy (75). Additionally, TLR2
has been imaged by ICC successfully in murine keratinocytes using confocal microscopy
(76). The success of these experiments indicate that trying different imaging techniques
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may also be required to assess co-localization between TLR2 and its co-receptors and
should be further pursued in the future.

Future directions
This project was the first to try to answer the question of how CA-MRSA isolates
are able to cause recurrent infections. Therefore, there are still a number of unanswered
questions and future directions that could be pursued.
The co-localization of TLR2 and its co-receptors is still a very important question
that should be addressed, but under our experimental conditions, it was difficult to
overcome the problem of protein A activity in our samples. Therefore, the
troubleshooting mentioned above should be pursued in order to assess these interactions.
Additionally, it has come to our attention that HaCat cells do not express TLR6 (28),
while primary skin cells do, so determining the interaction of TLR2 with this co-receptor
was removed from our experimental methods. HaCat cells are an immortalized cell line
and have variable expression of particular TLRs when compared to NHEKs and the
human epidermis (28). Therefore, in the future, these processes should be further
investigated in an in vitro model using NHEKs or an ex vivo skin infection model using
human epidermis samples to further establish the clinical relevance of our findings.
We have been unable to successfully separate nuclear and cytosolic extracts from
HaCat cells. This is possibly due to the large size and high protein content of these cells
(at least 5x more protein content than primary cells). We attempted to grow the cells up
in increasingly smaller cell culture dishes with increasing efficiency, but have still not
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been able to completely separate these extracts. Due to this, we were only able to assess
the total levels of phospho-NFκB, NFκB, and HMGB1 and were not able to look at the
cellular compartmentalization of these molecules. Looking at these total levels still
provided us with valuable information on if recurrent CA-MRSA isolates could decrease
the levels of NFκB activation as hypothesized. An alternative approach to look at
localization of NFκB in the future with total protein lysates, could be to probe total
protein Western Blots with an antibody against IκB, the inhibitor protein that keeps
NFκB in the cytoplasm. Upon phosphorylation of this protein, a nuclear localization
signal on NFκB is exposed and it is transported into the nucleus and the IκB protein is
tagged for degradation by the proteosome. Looking at the levels of phospho-IκB, as
compared to total levels of IκB, in total protein lysates could help to determine the
amount of nuclear NFκB indirectly. Though, based on our results, it does not appear that
NFκB translocation is effected in our assay due to the relatively stable levels of total PNFκB present, which requires NFκB to get into the nucleus prior to phosphorylation and
activation. Additionally, troubleshooting experiments should be continued to determine
the best protocol to separate the nuclear and cytosolic extracts of these samples in order
to directly determine the localization of these molecules post infection in keratinocytes.
In our ICC experiments, though the cells stained well in the vehicle control, it was
difficult to analyze the infection and vehicle groups with the same microscope settings
due to the differences in light intensity. Even with appropriate antibodies this would still
be a problem with any ICC experiments that utilize our experimental conditions with live
bacteria. Potentially in the future, the concentration of bacteria could be decreased to
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improve this problem. Additionally, confocal microscopy may be able to be used with
more appropriate antibodies to solve this problem. This method allows you focus more
closely and clearly on a smaller area of your slide that might allow for the avoidance of
the signal due to the bacteria binding the antibodies in the assay (80). Of note, it was
difficult to separate what was true staining of the cells and what staining was caused by
the bacteria in this assay. It may be useful to use a structural stain as well for these assays
to be able to visualize the boundaries of the cells instead of just the nucleus.
In the interest of time, I was not able to perform the propposed CHiP assays. In a
future project, the CHiP assays would give a good indication of possible changes at the
gene level, as opposed to the protein level where the rest of our experiments are focused.
Of note, since the binding of HMGB1 is known to be non-specific and low affinity, it
may be difficult to capture this binding interaction in a ChIP assay. Another possible
complication is the time frame of these experiments. We have proposed to look at a 6
hour time point, but it is also possible that these transcriptional changes could occur at
various time points during infection.
And finally, we believe that it would also be beneficial to further investigate the
effects of the secreted factors on TLR2-mediated cytokine secretion from keratinocytes
post infection as that is where we were able to see the most notable difference between
non-recurrent CA-MSSA and recurrent CA-MRSA treated groups. If these studies are to
be carried out, they should be done with additional MSSA isolates to make sure that the
findings still hold true when using clinical CA-MSSA isolates, as opposed to a lab MSSA
strain (Sa113). Additionally, these studies could be extended to a larger number of
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samples. Due to the large variability within our samples, this would be a good idea in
order to determine the clinical relevance of these findings. It would also be beneficial to
use a TLR2 neutralizing antibody to determine if these effects are in fact mediated by
TLR2, as opposed to some other recognition receptor in keratinocytes such as RAGE or
TLR4. Due to the above mentioned cell culture model limitations, it is very important to
develop ex vivo and in vitro models to further these findings. All of these experiments
would allow us to better understand the interactions between recurrent CA-MRSA
isolates and keratinocytes and would potentially allow for creation of better
immunomodulatory treatments for recurrent CA-MRSA infections in the clinic.

Summary and conclusions
In conclusion, the goal of this project was to better understand how recurrent CAMRSA bacterial isolates are able to establish recurrent infections in otherwise healthy
individuals. It was hypothesized that this was possible due to the production of a cellsurface virulence factor by these isolates that circumvented the TLR2 recognition
signaling pathway in keratinocytes. We found that exposure of keratinocytes to bacterial
culture supernatants from recurrent CA-MRSA isolates resulted in significantly
decreased secretion of pro-inflammatory (IL6 and TNFα) and anti-inflammatory (IL10)
cytokines. We further demonstrated that live keratinocyte infection with recurrent CAMRSA isolates did not significantly alter the production of these cytokines. We also
identified no significant difference in cytokine secretion from keratinocytes treated with
CA-MRSA isolates from subsequent infections of the same patient. Finally, we
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determined that recurrent CA-MRSA isolates did not decrease NFκB activation, total
TLR2 or CD14 protein levels, or HMGB1 secretion under our experimental conditions.
Our hypothesis suggesting that recurrent CA-MRSA cell surface virulence factors
were responsible for the decreased recognition by TLR2 host receptors proved to be
incorrect. Our findings suggest that a secreted virulence factor(s) may responsible for the
observed suppression of the inflammatory responses in keratinocytes post infection with
recurrent CA-MRSA isolates. These findings have important implications in the clinic
and in how physicians currently manage recurrent CA-MRSA infection.
The next steps should be to further determine the involvement of particular
secreted virulence factor(s) in order to potentially use it as a target for further
immunotherapies of recurrent CA-MRSA. As previously mentioned, a promising starting
point to these analyses is the further investigation of the SSL3 protein and its expression
during recurrent CA-MRSA infections. This protein was discovered relatively recently so
there are no commercial antibodies or PCR probes against this antigen. This means that
future work could be done in developing these tools for use in immunoassays in order to
determine if SSL3 may be playing a role in the ability of CA-MRSA to cause recurrent
infections. Based on our findings, we hypothesize that recurrent CA-MRSA isolates
upregulate SSL3 expression resulting in a decrease in TLR2-mediated cytokine secretion
from keratinocytes and therefore, decreased recognition of the pathogen in the skin.
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